WEST PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Intech, a global quantitative equity manager, proudly announces the launch of its U.S. Small-Mid Cap (SMID) Enhanced Plus strategy, backed by a substantial initial investment exceeding half a billion dollars. This new mandate underscores Intech’s sustained growth and strategic innovation, setting Intech U.S. Small-Mid Cap Enhanced Plus strategy apart from competitors with its unique approach and competitive fee structure.¹

Key Differentiators in a Competitive Market

Distinctive Alpha Source: Aims to use stock price volatility and correlations to deliver an uncorrelated alpha source for portfolios.
Enhanced Indexing: Moderate, systematic deviations from the index seek a higher probability of alpha capture and strong alignment with policy portfolios.
Lower Fees: Clients have the potential to capture a larger portion of returns from lower relative active management fees.¹

“Solving for emerging client needs is a key focus of the new Intech,” said Dr. Jose Marques, Chief Executive Officer at Intech. “This announcement continues the momentum since our successful management buyout that includes a recent $1.5 billion World ex-US mandate, a new strategic product partnership, and the launch of a client-funded defensive equity UCITS offering.”

“Our U.S. SMID Cap Enhanced Plus strategy leverages our core capabilities and is uniquely positioned to meet the challenges of today’s markets,” said Dr. Ryan Stever, Co-Chief Investment Officer at Intech. “In a more normalized rate environment with lower equity risk premiums, optimizing returns through enhanced indexing is more crucial than ever.”

We invite our clients, partners, and the investment community to learn more about this exciting new strategy and its benefits.

For further details, please contact:

Media Contact

Andre Prawoto
Head of Strategy
Phone: 1-561-776-2226
Email: aprawoto@intechinvestments.com

About Intech

Intech is a private, quantitative asset manager investing on behalf of institutional investors since 1987. Pioneers in the application of Stochastic Portfolio Theory, Intech continues to seek distinctive alpha sources for clients across six continents. For more information, visit www.intechinvestments.com

1. eVestment as of May 31, 2024. Includes 91 actively managed separate account strategies in the eVestment U.S. Small-Mid Cap Core Universe. The fee for Intech U.S. Small-Mid Cap Enhanced Plus strategy falls in the bottom 5th percentile for a $50 million mandate.

This press release does not constitute investment advice, nor should it be construed as an offer to sell, or the solicitation of an offer to buy, or a recommendation for any security or fund. The value of investments and the income derived from them can go down and up, and investors may not get back the amount originally invested. Past performance is not a guide to future performance. The information contained herein may be restricted by law, may not be reproduced or referred to without express written permission, or used in any jurisdiction or circumstance in which its use would be unlawful.

This item of content is a press release from a third party provider who make no warranties or representations in connection with this content and therefore PA can make no warranties in respect of its use.

Tags

More Like This

Intech Appoints Katherine Hardenbergh as Senior Vice President and Director of Research

Intech Announces Ryan Stever, Ph.D., as Co-Chief Investment Officer

EQT Private Capital Asia's Mid-Market Growth Fund closes at more than double its target size, raising USD 1.6 billion in total fund commitments

Rockefeller Asset Management Launches Fifth Equity UCITS Fund, Expands Small Cap Investment Solutions to Non-U.S. Investors

MSCI Strengthens Private Markets Leadership With Launch of 130 Indexes

Morningstar and PitchBook Introduce New Indexes to Provide Investors with Deeper Insight into Emerging Venture Capital Companies

Cinctive Expands Global Macro and Healthcare Investment Teams as Firm Marks Four Year Anniversary

Nordic Capital acquires majority share in IntegriChain, the only fully integrated platform for pharma commercialization and market access